Multiple myeloma (MM) is an incurable hematological malignancy. Immunodeficiency results in the incapability of immunity to eradicate both tumor cells and pathogens. Immunotherapies along with antibiotics and other anti-infectious agents are applied as substitutes for immunity in MM. Immunotherapies including monoclonal antibodies, immune checkpoints inhibitors, affinity- enhanced T cells, chimeric antigen receptor T cells and dendritic cell vaccines are revolutionizing MM treatment. By suppressing the pro-inflammatory milieu and pathogens, prophylactic and therapeutic antibiotics represent anti-tumor and anti-infection properties. It is expected that deeper understanding of infection, immunity and tumor physio-pathologies in MM will accelerate the optimization of combined therapies, thus improving prognosis in MM.
Li, L., Wang, L. (2019). Multiple Myeloma: What Do We Do About Immunodeficiency?. Journal of Cancer, 10(7), 1675-1684. https://doi.org/10.7150/jca.29993.
Li, L.; Wang, L. Multiple Myeloma: What Do We Do About Immunodeficiency?. J. Cancer 2019, 10 (7), 1675-1684. DOI: 10.7150/jca.29993.
Li L, Wang L. Multiple Myeloma: What Do We Do About Immunodeficiency?. J Cancer 2019; 10(7):1675-1684. doi:10.7150/jca.29993. https://www.jcancer.org/v10p1675.htm
Li L, Wang L. 2019. Multiple Myeloma: What Do We Do About Immunodeficiency?. J Cancer. 10(7):1675-1684.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.